Panacea Biotec [PANACEABIO] vs Albert David [ALBERTDAVD] Detailed Stock Comparison
Panacea Biotec
NSE
Loading...
Albert David
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Panacea Biotec wins in 4 metrics, Albert David wins in 12 metrics, with 0 ties. Albert David appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Panacea Biotec | Albert David | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 91.93 | 73.13 | Albert David |
| Price-to-Book Ratio | 3.00 | 1.17 | Albert David |
| Debt-to-Equity Ratio | 2.67 | 3.14 | Panacea Biotec |
| PEG Ratio | N/A | -1.26 | N/A |
| EV/EBITDA | 0.00 | -23.44 | Albert David |
| Profit Margin (TTM) | 1.88% | 1.93% | Albert David |
| Operating Margin (TTM) | -2.26% | -18.48% | Panacea Biotec |
| Return on Equity | -1.01% | 4.38% | Albert David |
| Return on Assets (TTM) | -0.65% | 3.36% | Albert David |
| Free Cash Flow (TTM) | $-776.80M | $-432.92M | Albert David |
| Dividend Yield | N/A | 1.86% | N/A |
| 1-Year Return | 104.85% | -44.19% | Panacea Biotec |
| Price-to-Sales Ratio (TTM) | 4.10 | 1.42 | Albert David |
| Enterprise Value | $0 | $2.31B | Albert David |
| EV/Revenue Ratio | 0.00 | 0.71 | Panacea Biotec |
| Gross Profit Margin (TTM) | 60.70% | 64.18% | Albert David |
| Revenue per Share (TTM) | $100 | $573 | Albert David |
| Earnings per Share (Diluted) | $-1.39 | $11.01 | Albert David |
| Beta (Stock Volatility) | N/A | 0.07 | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Panacea Biotec vs Albert David Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Panacea Biotec | 0.33% | -5.01% | -4.26% | -22.93% | 24.66% | -6.78% |
| Albert David | 1.00% | 0.90% | -11.91% | -2.33% | -7.68% | -39.72% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Panacea Biotec | 104.85% | 205.36% | 153.92% | 201.54% | 120.01% | 81.18% |
| Albert David | -44.19% | 46.90% | 83.23% | 152.52% | 152.52% | 152.52% |
Performance & Financial Health Analysis: Panacea Biotec vs Albert David
| Metric | PANACEABIO | ALBERTDAVD |
|---|---|---|
| Market Information | ||
| Market Cap | ₹25.12B | ₹4.63B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 246,971 | 6,415 |
| 90 Day Avg. Volume | 201,025 | 5,625 |
| Last Close | ₹411.45 | ₹816.15 |
| 52 Week Range | ₹177.30 - ₹581.90 | ₹762.60 - ₹1,753.95 |
| % from 52W High | -29.29% | -53.47% |
| All-Time High | ₹581.90 (Apr 28, 2025) | ₹1,753.95 (Sep 02, 2024) |
| % from All-Time High | -29.29% | -53.47% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.49% | -0.21% |
| Quarterly Earnings Growth | 0.03% | -0.58% |
| Financial Health | ||
| Profit Margin (TTM) | 0.02% | 0.02% |
| Operating Margin (TTM) | -0.02% | -0.18% |
| Return on Equity (TTM) | -0.01% | 0.04% |
| Debt to Equity (MRQ) | 2.67 | 3.14 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹136.92 | ₹687.70 |
| Cash per Share (MRQ) | N/A | ₹426.93 |
| Operating Cash Flow (TTM) | ₹-1,547,900,000 | ₹-111,139,000 |
| Levered Free Cash Flow (TTM) | ₹-83,700,000 | ₹172.01M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.86% |
| Last 12-Month Dividend | ₹0.00 | ₹16.50 |
Valuation & Enterprise Metrics Analysis: Panacea Biotec vs Albert David
| Metric | PANACEABIO | ALBERTDAVD |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 91.93 | 73.13 |
| Forward P/E | N/A | N/A |
| PEG Ratio | N/A | -1.26 |
| Price to Sales (TTM) | 4.10 | 1.42 |
| Price to Book (MRQ) | 3.00 | 1.17 |
| Market Capitalization | ||
| Market Capitalization | ₹25.12B | ₹4.63B |
| Enterprise Value | ₹0 | ₹2.31B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.00 | 0.71 |
| Enterprise to EBITDA | 0.00 | -23.44 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.07 |
| Book Value per Share (MRQ) | ₹136.92 | ₹687.70 |
Financial Statements Comparison: Panacea Biotec vs Albert David
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PANACEABIO | ALBERTDAVD |
|---|---|---|
| Revenue/Sales | ₹1.33B | ₹705.66M |
| Cost of Goods Sold | ₹520.80M | ₹252.80M |
| Gross Profit | ₹804.50M | ₹452.86M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹-353.00M | ₹-130.43M |
| EBITDA | ₹-182.90M | ₹113.82M |
| Pre-Tax Income | ₹-400,000 | ₹84.38M |
| Income Tax | ₹19.50M | ₹5.01M |
| Net Income (Profit) | ₹-19.90M | ₹79.38M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PANACEABIO | ALBERTDAVD |
|---|---|---|
| Cash & Equivalents | ₹821.30M | ₹4.17M |
| Total Current Assets | ₹5.45B | ₹3.54B |
| Total Current Liabilities | ₹3.67B | ₹1.04B |
| Long-Term Debt | ₹222.10M | ₹13.31M |
| Total Shareholders Equity | ₹8.31B | ₹3.92B |
| Retained Earnings | N/A | ₹2.49B |
| Property, Plant & Equipment | ₹5.43B | ₹100.54M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PANACEABIO | ALBERTDAVD |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | PANACEABIO | ALBERTDAVD |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 246,971 | 6,415 |
| Average Daily Volume (90 Day) | 201,025 | 5,625 |
| Shares Outstanding | 61.25M | 5.71M |
| Float Shares | 15.44M | 2.05M |
| % Held by Insiders | 0.73% | 0.65% |
| % Held by Institutions | 0.00% | 0.02% |
Dividend Analysis & Yield Comparison: Panacea Biotec vs Albert David
| Metric | PANACEABIO | ALBERTDAVD |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹16.50 |
| Last 12-Month Dividend Yield | N/A | 1.86% |
| 3-Year Avg Annual Dividend | ₹0.00 | ₹17.50 |
| 3-Year Avg Dividend Yield | N/A | 1.16% |
| 3-Year Total Dividends | ₹0.00 | ₹52.50 |
| Ex-Dividend Date | N/A | Jul 25, 2025 |